Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia.

Frontiers in Oncology
Fu-Jia LiuYang Shen

Abstract

The clinically ideal time point and optimal approach for the assessment of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) are still inconclusive. We investigated the clinical value of multiparameter flow cytometry-based MRD (MFC MRD) after induction (n = 492) and two cycles of consolidation (n = 421). The latter time point was proved as a superior indicator with independent prognostic significance for both relapse-free survival (RFS, HR = 3.635, 95% CI: 2.433-5.431, P <0.001) and overall survival (OS: HR = 3.511, 95% CI: 2.191-5.626, P <0.001). Furthermore, several representative molecular MRD markers were compared with the MFC MRD. Both approaches can establish prognostic value in patients with NPM1 mutations, and FLT3, C-KIT, or N-RAS mutations involved in kinase-related signaling pathways, while the combination of both techniques further refined the risk stratification. The detection of RUNX1-RUNX1T1 fusion transcripts achieved a considerable net reclassification improvement in predicting the prognosis. Conversely, for patients with biallelic CEBPA or DNMT3A mutations, only the MFC method was recommended due to the poor prognostic discriminability in tracking mutant transcripts. In conclusion...Continue Reading

References

Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David GrimwadeAlan K Burnett
Sep 16, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela CilloniDavid Grimwade
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monique TerwijnGerrit J Schuurhuis
Aug 26, 2015·JAMA : the Journal of the American Medical Association·Jeffery M KlcoTimothy J Ley
Jan 21, 2016·The New England Journal of Medicine·Adam IveyUNKNOWN UK National Cancer Research Institute AML Working Group
Apr 8, 2017·Leukemia·C S HouriganR B Walter
Apr 28, 2017·International Journal of Laboratory Hematology·N M CruzM L Guzman
Mar 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvie D FreemanNigel H Russell
Mar 31, 2018·The New England Journal of Medicine·Mojca Jongen-LavrencicPeter J M Valk
Aug 7, 2018·Lancet·Nicholas J ShortJorge E Cortes
Nov 9, 2018·International Journal of Molecular Sciences·Fabio ForghieriMario Luppi
Aug 10, 2019·Frontiers in Oncology·Maria Teresa VosoFrancesco Buccisano
Dec 6, 2019·British Journal of Haematology·Jack GhannamChristopher S Hourigan

❮ Previous
Next ❯

Software Mentioned

R
SPSS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Leukemia
Bruno PaivaPETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
Pulkit Rastogi, Man Updesh Singh Sachdeva
© 2021 Meta ULC. All rights reserved